Enovix Corporation (ENVX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now — Positive
ENVX Zacks Investment Research — July 28, 2025Enovix Corporation (ENVX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM — Neutral
TEM GlobeNewsWire — July 28, 2025NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating MediaAlpha Inc. for potential violations of securities laws — Neutral
MAX GlobeNewsWire — July 28, 2025PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

Fubo Sees Disney, Hulu + Live TV Deal Closing Earlier Than Anticipated — Positive
DIS FUBO Deadline — July 28, 2025Fubo has accelerated the expected timeline for closing its sale to Disney, now anticipating the transaction will close in the fourth quarter of this year or the first three months of 2026. It requires regulatory approval with a review ongoing at the Department of Justice.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS — Neutral
HIMS GlobeNewsWire — July 28, 2025NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT — Neutral
SRPT GlobeNewsWire — July 28, 2025NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Can Optum Support UnitedHealth's Profit Amid Industry Headwinds? — Negative
UNH Zacks Investment Research — July 28, 2025UNH leans on Optum's diversified growth and value-based care to counter insurance sector margin pressure in Q2.

Bank of Marin (BMRC) Q2 Earnings Miss Estimates — Negative
BMRC Zacks Investment Research — July 28, 2025Bank of Marin (BMRC) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.06 per share a year ago.

Here's Why BOK Financial (BOKF) is a Strong Momentum Stock — Positive
BOKF Zacks Investment Research — July 28, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Exelixis (EXEL) is a Strong Momentum Stock — Positive
EXEL Zacks Investment Research — July 28, 2025The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Barrick Mining (B) is a Strong Momentum Stock — Positive
B Zacks Investment Research — July 28, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Dentsply International (XRAY) is a Strong Momentum Stock — Positive
XRAY Zacks Investment Research — July 28, 2025The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

These Analysts Cut Their Forecasts On Charter Communications Following Q2 Earnings — Negative
CHTR Benzinga — July 28, 2025Charter Communications, Inc. CHTR reported a second-quarter EPS miss on Friday.

PayPal launches crypto payment service for US merchants — Positive
PYPL Proactive Investors — July 28, 2025PayPal Holdings Inc (NASDAQ:PYPL, ETR:2PP) said on Monday it is launching “Pay with Crypto,” a new service that enables US merchants to accept payments in over 100 cryptocurrencies, including Bitcoin, Ethereum, Tether, and Solana, as part of a broader move to reduce cross-border transaction costs and tap into the expanding digital asset market. The service, rolling out in the coming weeks, charges a 0.99% transaction fee—significantly below traditional international payment processing costs—and offers instant conversion to fiat or stablecoins.

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm — Neutral
CAPR PRNewsWire — July 28, 2025LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 9, 2024, and July 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2025.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Centene Corporation of Class Action Lawsuit and Upcoming Deadlines - CNC — Neutral
CNC GlobeNewsWire — July 28, 2025NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centene Corporation (“Centene” or the “Company”)(NYSE: CNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm — Neutral
RXST PRNewsWire — July 28, 2025LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 7, 2024 and July 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 22, 2025.

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm — Neutral
REPL PRNewsWire — July 28, 2025LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 22, 2024 and July 21, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 22, 2025.

ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm — Neutral
ANRO PRNewsWire — July 28, 2025LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on or about February 2, 2024 and/or between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), are encouraged to contact the firm before September 19, 2025.
